According to the Zhitong Finance APP, Pharscin Pharma (002907.SZ) announced that the company recently received the "Drug Clinical Trial Approval Notification" issued by the National Medical Products Administration (hereinafter referred to as "NMPA"). After review, the clinical trial application for CX001 sustained-release tablets submitted on April 16, 2025, meets the relevant requirements for drug registration, and approval has been granted to conduct clinical trials for the indication "for the treatment of postherpetic neuralgia."

CX001 sustained-release tablets are self-developed products of the company, which modify the immediate-release formulation into a sustained-release formulation (gastric-retentive sustained-release tablets). This sustained-release formulation can reduce the frequency of administration, increase patient compliance, and improve sleep quality. The indication for this clinical trial application is for the treatment of postherpetic neuralgia